| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Yvette van Kooyk | Q29914012 |
| Tanja D de Gruijl | Q90913412 | ||
| Joke den Haan | Q60250994 | ||
| Dieke van Dinther | Q60252717 | ||
| P2093 | author name string | Rieneke van de Ven | |
| Dorian A Stolk | |||
| P2860 | cites work | APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif | Q22003753 |
| Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules | Q22011207 | ||
| Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin | Q24315864 | ||
| CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes | Q24320164 | ||
| Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen | Q24321985 | ||
| Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development | Q24645273 | ||
| ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells | Q24672345 | ||
| Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production | Q24685926 | ||
| Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies | Q26752558 | ||
| The development and maintenance of resident macrophages | Q26774975 | ||
| Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses | Q26777948 | ||
| Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity | Q26782131 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Tissue-resident macrophages | Q26991488 | ||
| Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169 | Q27301034 | ||
| Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity | Q27489852 | ||
| Different cross-presentation pathways in steady-state and inflammatory dendritic cells | Q28115137 | ||
| Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains | Q28115533 | ||
| Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues | Q28214619 | ||
| Structure and function of the spleen | Q28264813 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| The mannose receptor | Q28274841 | ||
| Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B | Q28293931 | ||
| Siglecs and their roles in the immune system | Q28294469 | ||
| Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation | Q28393754 | ||
| Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages | Q28477167 | ||
| Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells | Q28505356 | ||
| The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues | Q28510383 | ||
| Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells | Q28591976 | ||
| Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes | Q28592638 | ||
| Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses | Q28616569 | ||
| EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture | Q29347264 | ||
| A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin | Q29391980 | ||
| In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens | Q29615098 | ||
| Differential antigen processing by dendritic cell subsets in vivo | Q29615177 | ||
| Taking dendritic cells into medicine | Q29619243 | ||
| Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages | Q29620142 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo | Q30080006 | ||
| In vivo analysis of dendritic cell development and homeostasis | Q30492687 | ||
| Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist | Q30573156 | ||
| Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma | Q30843481 | ||
| Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells | Q30873503 | ||
| Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses | Q33229932 | ||
| Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network | Q33590503 | ||
| Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells | Q33591529 | ||
| Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. | Q33723950 | ||
| The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells | Q33902379 | ||
| Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells | Q33902421 | ||
| Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens by dendritic cells | Q33911282 | ||
| CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. | Q33928441 | ||
| High sensitivity of cancer exome-based CD8 T cell neo-antigen identification | Q33930588 | ||
| Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR | Q34163004 | ||
| Skin immune sentinels in health and disease | Q34165173 | ||
| Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression | Q36060263 | ||
| Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny | Q36263627 | ||
| Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses | Q36278067 | ||
| Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state | Q36294401 | ||
| Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells | Q36333494 | ||
| Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified | Q36367631 | ||
| Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance | Q36376611 | ||
| In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination | Q36402359 | ||
| The BXH2 mutation in IRF8 differentially impairs dendritic cell subset development in the mouse | Q36445813 | ||
| A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo | Q36452968 | ||
| Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option | Q36571695 | ||
| Engineered lentivector targeting of dendritic cells for in vivo immunization | Q36629181 | ||
| Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand | Q36725571 | ||
| The multifaceted biology of plasmacytoid dendritic cells | Q36731249 | ||
| Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors | Q36775202 | ||
| Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node | Q36783070 | ||
| Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells | Q36822691 | ||
| Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation | Q36835483 | ||
| IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses | Q36882237 | ||
| Targeted cancer therapy: conferring specificity to cytotoxic drugs | Q36912991 | ||
| Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting | Q36939901 | ||
| The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement | Q36941087 | ||
| CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice | Q36945969 | ||
| Distinct Transcriptional Programs Control Cross-Priming in Classical and Monocyte-Derived Dendritic Cells | Q37086985 | ||
| Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. | Q37095794 | ||
| Identification of a dendritic cell receptor that couples sensing of necrosis to immunity | Q37164859 | ||
| Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition | Q37277188 | ||
| CD301b⁺ dermal dendritic cells drive T helper 2 cell-mediated immunity | Q37284012 | ||
| Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species | Q37293474 | ||
| Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein | Q37375709 | ||
| A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy | Q37457907 | ||
| Transcriptional Control of Dendritic Cell Development. | Q37468541 | ||
| Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma | Q37473978 | ||
| RAB43 facilitates cross-presentation of cell-associated antigens by CD8α+ dendritic cells. | Q37500322 | ||
| Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. | Q37500375 | ||
| Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors. | Q42106951 | ||
| Langerin-expressing dendritic cells in human tissues are related to CD1c+ dendritic cells and distinct from Langerhans cells and CD141high XCR1+ dendritic cells. | Q42108118 | ||
| Origin of the lamina propria dendritic cell network | Q42117974 | ||
| Dendritic cell-associated lectin 2 (DCAL2) defines a distinct CD8α- dendritic cell subset | Q42143775 | ||
| Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. | Q42202638 | ||
| Ex vivo generation of interstitial and Langerhans cell-like dendritic cell subset-based vaccines for hematological malignancies | Q42219829 | ||
| In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity | Q42258180 | ||
| Cationic amphiphile with shikimic acid headgroup shows more systemic promise than its mannosyl analogue as DNA vaccine carrier in dendritic cell based genetic immunization | Q42830712 | ||
| Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant | Q42933566 | ||
| Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells | Q43120646 | ||
| Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen | Q43468956 | ||
| Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells | Q43552844 | ||
| DCIR acts as an inhibitory receptor depending on its immunoreceptor tyrosine-based inhibitory motif | Q43883767 | ||
| The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells | Q43891685 | ||
| Two distinct types of Langerhans cells populate the skin during steady state and inflammation | Q43924469 | ||
| The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells | Q43937127 | ||
| Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection | Q44331115 | ||
| Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses | Q44606736 | ||
| Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition | Q44879296 | ||
| Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy | Q44942720 | ||
| Macrophage heterogeneity in lymphoid tissues | Q44969513 | ||
| Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells | Q45153139 | ||
| Laminarin-mediated targeting to Dectin-1 enhances antigen-specific immune responses | Q45348881 | ||
| The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells | Q45653426 | ||
| DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production | Q46084329 | ||
| Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes | Q46216588 | ||
| Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions | Q46626936 | ||
| Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation | Q46674193 | ||
| Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo | Q46804413 | ||
| Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells | Q46934267 | ||
| Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. | Q47687570 | ||
| Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. | Q50064816 | ||
| Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. | Q50457532 | ||
| High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. | Q50773034 | ||
| CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. | Q50787445 | ||
| Lectin Receptors Expressed on Myeloid Cells. | Q51364012 | ||
| Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. | Q51475003 | ||
| Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. | Q51765801 | ||
| Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. | Q51773605 | ||
| MGL-mediated internalization and antigen presentation by dendritic cells: a role for tyrosine-5. | Q51796251 | ||
| Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. | Q51803715 | ||
| The vast majority of CLA+ T cells are resident in normal skin. | Q51984006 | ||
| Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. | Q52049353 | ||
| Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. | Q52907264 | ||
| Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. | Q53085484 | ||
| Self-renewal capacity of human epidermal Langerhans cells: observations made on a composite tissue allograft. | Q53306436 | ||
| Origin of dendritic cells in peripheral lymphoid organs of mice. | Q53558035 | ||
| A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. | Q53619786 | ||
| Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. | Q54047916 | ||
| Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans. | Q54445726 | ||
| Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy. | Q39482884 | ||
| Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity | Q39621141 | ||
| Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor | Q39647119 | ||
| Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses | Q39664739 | ||
| Characterization of murine MGL1 and MGL2 C-type lectins: distinct glycan specificities and tumor binding properties | Q39892006 | ||
| Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity | Q39981419 | ||
| Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. | Q40000399 | ||
| Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production | Q40015356 | ||
| In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models | Q40076581 | ||
| The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells | Q40172102 | ||
| Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells | Q40179067 | ||
| Modular expression analysis reveals functional conservation between human Langerhans cells and mouse cross-priming dendritic cells. | Q40253946 | ||
| Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration | Q40290035 | ||
| Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. | Q40297027 | ||
| Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes. | Q40408582 | ||
| Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells | Q40440515 | ||
| Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells | Q40443196 | ||
| Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. | Q40462465 | ||
| Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells | Q40565323 | ||
| Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules | Q40587048 | ||
| Antigen targeting reveals splenic CD169+ macrophages as promoters of germinal center B-cell responses | Q40593868 | ||
| Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection | Q40617421 | ||
| A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant | Q40787014 | ||
| Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells | Q40952120 | ||
| In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses | Q41054995 | ||
| Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes | Q41080657 | ||
| Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1(+) DCs in mouse and human and distinguishes them from Langerhans cells | Q41112925 | ||
| Klf4 expression in conventional dendritic cells is required for T helper 2 cell responses. | Q41214702 | ||
| Targeting to porcine sialoadhesin receptor improves antigen presentation to T cells. | Q41537516 | ||
| Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates | Q41610389 | ||
| Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. | Q41819217 | ||
| IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia | Q37615661 | ||
| Induction of innate and adaptive immunity by delivery of poly dA:dT to dendritic cells | Q37626826 | ||
| Deciphering the transcriptional network of the dendritic cell lineage | Q37700905 | ||
| The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma | Q37890966 | ||
| CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. | Q37892578 | ||
| An evolutionary perspective on C-type lectins in infection and immunity | Q37979878 | ||
| Multivalency as a chemical organization and action principle | Q38041060 | ||
| The physiological role of DC-SIGN: a tale of mice and men. | Q38100871 | ||
| Skin-resident antigen-presenting cells: instruction manual for vaccine development | Q38117141 | ||
| Inflammatory dendritic cells in mice and humans | Q38119788 | ||
| Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14(+) Cells at the Cross-Roads of Immune Activation and Suppression | Q38170109 | ||
| Cross-presentation by human dendritic cell subsets | Q38170876 | ||
| The origins and functions of dendritic cells and macrophages in the skin | Q38214043 | ||
| Human skin dendritic cells in health and disease | Q38258710 | ||
| Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting. | Q38300387 | ||
| Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens | Q38301229 | ||
| Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating β-glucan | Q38316887 | ||
| Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. | Q38334463 | ||
| Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization | Q38336731 | ||
| High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin | Q38341351 | ||
| Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells | Q38356938 | ||
| Cross-Presentation in Mouse and Human Dendritic Cells | Q38527616 | ||
| Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells | Q38597659 | ||
| Langerhans cell origin and regulation | Q38629610 | ||
| Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment | Q38636864 | ||
| Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. | Q38776860 | ||
| Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. | Q38809786 | ||
| Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic β-Glucan Dectin-1 Agonist to Protein Antigen | Q38888077 | ||
| High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma | Q38926293 | ||
| Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses | Q38986327 | ||
| Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. | Q38994851 | ||
| Antigen-Presenting Cells in the Skin | Q39146789 | ||
| DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues | Q39374974 | ||
| CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. | Q39448429 | ||
| Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells | Q85634389 | ||
| Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation | Q86623565 | ||
| Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study | Q87455611 | ||
| Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming | Q87870332 | ||
| Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. | Q54598048 | ||
| Antigen crosspresentation by human plasmacytoid dendritic cells. | Q55044627 | ||
| CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. | Q55053710 | ||
| F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells | Q56880701 | ||
| Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients | Q56901384 | ||
| Antigen Presentation the Macrophage Way | Q56988446 | ||
| The C-Type Lectin Clec12A Present on Mouse and Human Dendritic Cells Can Serve as a Target for Antigen Delivery and Enhancement of Antibody Responses | Q57133306 | ||
| Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation | Q57195316 | ||
| Tumor-Associated Tn-MUC1 Glycoform Is Internalized through the Macrophage Galactose-Type C-Type Lectin and Delivered to the HLA Class I and II Compartments in Dendritic Cells | Q57195392 | ||
| Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation | Q57261981 | ||
| Cell-mediated immune responses to MUC1 fusion protein coupled to mannan | Q57594351 | ||
| Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients | Q57779512 | ||
| Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells | Q58619819 | ||
| Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion | Q58619877 | ||
| Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN | Q58619885 | ||
| The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells | Q58619899 | ||
| DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells | Q58619914 | ||
| In Vivo Targeting of DC-SIGN-positive Antigen-presenting Cells in a Nonhuman Primate Model | Q58619996 | ||
| Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection | Q74186524 | ||
| Development of a cancer vaccine: peptides, proteins, and DNA | Q74194968 | ||
| Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response | Q79983205 | ||
| Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1 | Q80057988 | ||
| Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo | Q80825231 | ||
| Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma | Q81019105 | ||
| Single chain antibody fragments for the selective targeting of antigens to dendritic cells | Q81647965 | ||
| The C-type lectin macrophage galactose-type lectin impedes migration of immature APCs | Q81803363 | ||
| Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule | Q82994736 | ||
| Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content | Q83289196 | ||
| Delivery of antigen to sialoadhesin or CD163 improves the specific immune response in pigs | Q84072295 | ||
| Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles | Q84074937 | ||
| Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants | Q84396239 | ||
| Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation | Q84450879 | ||
| Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation | Q84547662 | ||
| Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. | Q36014997 | ||
| Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. | Q36021163 | ||
| Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages | Q36021832 | ||
| Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions | Q36054488 | ||
| Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice | Q34214131 | ||
| Human dermal CD14⁺ cells are a transient population of monocyte-derived macrophages | Q34244161 | ||
| Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody | Q34310888 | ||
| KLRL1, a novel killer cell lectinlike receptor, inhibits natural killer cell cytotoxicity | Q34331615 | ||
| Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity | Q34341859 | ||
| Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance | Q34342500 | ||
| Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. | Q34406488 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| Dendritic cell immunotherapy: clinical outcomes | Q34511606 | ||
| Combination immunotherapy: a road map. | Q34552128 | ||
| Transcriptional profiling of human dendritic cell populations and models--unique profiles of in vitro dendritic cells and implications on functionality and applicability | Q34558328 | ||
| Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. | Q34573130 | ||
| Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. | Q34623431 | ||
| Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity | Q34625640 | ||
| T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells | Q34626234 | ||
| Survey of immune-related, mannose/fucose-binding C-type lectin receptors reveals widely divergent sugar-binding specificities | Q34661542 | ||
| IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. | Q34854946 | ||
| Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge | Q34855420 | ||
| Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia | Q34918881 | ||
| DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice | Q34939255 | ||
| Intestinal lamina propria dendritic cell subsets have different origin and functions. | Q35001346 | ||
| Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin | Q35030843 | ||
| Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy | Q35069876 | ||
| IRF8 mutations and human dendritic-cell immunodeficiency | Q35106002 | ||
| Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients | Q35116211 | ||
| Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. | Q35119724 | ||
| Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. | Q35148879 | ||
| Proinflammatory microenvironments within the intestine regulate the differentiation of tissue-resident CD8⁺ T cells responding to infection | Q35202406 | ||
| Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice | Q35227905 | ||
| CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells | Q35567056 | ||
| Self- and nonself-recognition by C-type lectins on dendritic cells | Q35698392 | ||
| Characterization of resident and migratory dendritic cells in human lymph nodes | Q35894149 | ||
| The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice | Q35913706 | ||
| Mannose receptor-targeted vaccines | Q35967297 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P921 | main subject | dendritic cell | Q506253 |
| neoplasm | Q1216998 | ||
| cancer vaccine | Q2378309 | ||
| helper-inducer T-lymphocytes | Q65983548 | ||
| C-type lectins | Q66023678 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-07-20 | |
| 2017-10-01 | |||
| P1433 | published in | Journal of Leukocyte Biology | Q1524048 |
| P1476 | title | Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines |
| Q62589146 | Activation of CD8⁺ T Cell Responses after Melanoma Antigen Targeting to CD169⁺ Antigen Presenting Cells in Mice and Humans |
| Q57094380 | CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential |
| Q58761430 | Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma |
| Q90161713 | Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting |
| Q52721336 | Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus. |
| Q92988727 | Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination |
| Q90169710 | Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets |
| Q61812341 | Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy |
| Q98946621 | Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans |
| Q51410365 | Regulation of the Cell Biology of Antigen Cross-Presentation. |
| Q99602523 | Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides |
| Q52584422 | Targeting Mycobacterium tuberculosis Antigens to Dendritic Cells via the DC-Specific-ICAM3-Grabbing-Nonintegrin Receptor Induces Strong T-Helper 1 Immune Responses. |
| Q55378528 | Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I. |
| Q64057499 | Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses |
| Q89965725 | Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors |
Search more.